Important Information
Please note, we need you to ….
- Read the important documents for this study
- If you are interested, look at the dates that this study is being run (cohort visit planners) and reply to our email (don’t re-register online) to let us know which cohort(s) you are available for
- We will ring you to check your suitability and provide further information about the study
- We will make you a screening appointment at NZCR Christchurch. You will need to attend at the scheduled time if you wish to take part in the study
Study Information
New Zealand Clinical Research is trialing an experimental drug that may potentially be used for the treatment for Parkinson’s Disease in the future.
Parkinson’s Disease affects approximately 1-2% of the population over the age of 60. It is a progressively disabling disease with symptoms of tremor, rigidity, and postural instability. It can affect a person’s mental health, and cause constipation, pain and sleep disorders.
The drug being trialed seeks to prevent and/or reverse the mutant processes causing disease in Parkinson’s patients. This differs from traditional treatments which provide relief from symptoms which become less effective over time.
This study (2023 FULL 15408) is being funded by Neuron23 and has been approved by the Health and Disability Ethics Committee.
Study Candidtes
- Healthy males and females
- Aged 18 – 80 years
- BMI 18 – 32 kg/m2
- Non-smokers (no cigarettes in the last 14 days) or Ex-smokers.
- Not currently taking any medication
- Willing to have x2 Lumbar Punctures
What is Involved?
Part B (MAD):
Study Visits: 8 -night stays
Outpatient visits: 1 visit
Reimbursement: $6,000 (less tax)